세계의 피부암 진단 시장 보고서(2025년)

Skin cancer diagnostics involve the processes and methods employed by healthcare professionals to identify and confirm the presence of skin cancer in individuals. These diagnostics typically encompass a combination of clinical examination, imaging techniques, and laboratory tests, aimed at evaluating suspicious skin lesions and assessing the extent and characteristics of the cancer.

The main types of skin cancer diagnostics include basal cell carcinoma, squamous cell carcinoma, malignant melanoma, and others. Basal Cell Carcinoma is the most prevalent form of skin cancer, originating from the basal cells of the skin's lower epidermis. Various diagnostic and therapeutic methods are widely applied in hospitals, clinics, laboratories, and other healthcare settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The skin cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides skin cancer diagnostics market statistics, including skin cancer diagnostics industry global market size, regional shares, competitors with skin cancer diagnostics market share, detailed skin cancer diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the skin cancer diagnostics industry. This skin cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The skin cancer diagnostics market size has grown strongly in recent years. It will grow from $3.13 billion in 2024 to $3.38 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increased incidence of skin cancer, growing aging population, awareness and education programs, government initiatives for early detection.

The skin cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.67 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to rising sun exposure awareness, personalized medicine approaches, telemedicine and remote monitoring, global expansion of healthcare infrastructure. Major trends in the forecast period include integration of digital health platforms, innovative skin cancer drugs, multi-disciplinary approaches, dermatopathology innovations, patient education and awareness.

The forecast of 8.4% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. early detection efforts by inflating prices of Artificial intelligence-powered dermatoscopes and Mohs surgery kits developed in Australia and Italy, resulting in delayed melanoma diagnoses and higher oncology surgical expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The skin cancer diagnostics market is poised for growth, driven by the increasing incidence of melanoma. Melanoma, a form of skin cancer arising from melanin-producing cells, necessitates effective diagnostics for early detection and accurate treatment planning. In 2023, the American Cancer Society reported a rise in male melanoma cases in the United States from 57,180 in 2022 to 58,120 in 2023. According to the American Society of Clinical Oncology, melanoma constitutes approximately 1% of diagnosed skin cancers in the United States but is a leading cause of skin cancer-related mortality, projected to claim 7,990 lives in 2023. Consequently, the escalating incidence of melanoma is propelling the skin cancer diagnostics market's growth.

The skin cancer diagnostics market is anticipated to benefit from increased investments in cancer research. This involves allocating financial resources to scientific endeavors aimed at studying, preventing, diagnosing, and treating cancer. Such funding supports the development of innovative technologies, including advanced imaging techniques, molecular diagnostics, and biomarker identification for skin cancer diagnostics. For instance, in March 2022, the Department of Health and Aged Care in Australia allocated $893.5 million to enhance cancer services and outcomes. This substantial investment in cancer research is expected to fuel advancements in skin cancer diagnostics.

Leading companies in the skin cancer diagnostics market are concentrating on developing innovative products, such as the PRAME protein, to improve detection and treatment strategies for melanoma and other skin cancers. PRAME (Preferentially Expressed Antigen in Melanoma) is a cancer/testis antigen that has demonstrated promise as a biomarker for melanoma diagnostics. For example, in October 2022, Roche, a Switzerland-based global healthcare company, introduced the PRAME (EPR20330) Antibody. This antibody is specifically designed to detect PRAME protein expression in tissue samples from patients suspected of having melanoma. It aids in differentiating between benign and malignant lesions, as the presence of PRAME expression indicates malignancy, which is crucial for accurate diagnosis and treatment planning.

Major players in the skin cancer diagnostics market are directing their efforts toward advanced services, including AI-powered pop-up clinics, to gain a competitive advantage. AI-powered pop-up clinics utilize artificial intelligence technologies to offer efficient and technologically advanced medical services. In January 2023, Skin Check Champions, in collaboration with The University of South Australia and The Hospital Research Foundation, introduced an AI-powered pop-up clinic dedicated to skin cancer diagnosis. Managed by nurses, this clinic captures high-quality lesion images, subjecting them to AI algorithms for preliminary diagnoses, later confirmed by local general practitioners.

In August 2022, Bristol Myers Squibb, a US-based biopharmaceutical company, acquired Turning Point Therapeutics Inc. for an undisclosed amount. This strategic acquisition enhances Bristol's portfolio with investigational medicines targeting common oncogenic mutations, including repotrectinib. Turning Point Therapeutics, Inc., is a US-based pharmaceutical company specializing in targeted therapies for breast, ovarian, and melanoma cancer treatment.

Major companies operating in the skin cancer diagnostics market include Pfizer Inc., F. Hoffmann-La Roche Limited, Merck & Co., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Eli Lilly and Company, Canon Medical Systems Corporation, Amgen Inc., GE Healthcare, Daiichi Sankyo Company Limited., National Cancer Institute, Agilent Technologies Inc., bioMerieux SA, Teva Pharmaceutical Industries, Bruker Corp, Almirall, Genentech, Castle Biosciences, Sun Pharmaceutical Industries Limited., American Academy of Dermatology, Biolitec Ag, Alma Lasers, DermTech Inc., SkylineDx BV, DermLite LLC, AMLo Biosciences Limited

North America was the largest region in the skin cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the skin cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the skin cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The skin cancer diagnostics market consists of revenues earned by entities by providing skin cancer diagnostics services such as diagnostic tests, visual inspection, dermoscopy, biopsy, imaging techniques (ultrasound, CT scan, MRI), laboratory tests (immunohistochemistry, molecular testing, genetic analysis). The market value includes the value of related goods sold by the service provider or included within the service offering. The skin cancer diagnostics market also includes sales of dermatoscope, biopsy tools, imaging equipment (ultrasound, CT scanners, MRI machines), molecular testing kits, immunohistochemistry (IHC) kits, laboratory analysis software. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Skin Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on skin cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for skin cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The skin cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cancer Type: Basal Cell Carcinoma, Squamous Cell Carcinoma, Malignant Melanoma, Other Cancer Types
• 2) By Type: Diagnosis, Therapeutics
• 3) By Application: Hospital, Clinic, Laboratory, Other Applications
• Subsegments:
• 1) By Basal Cell Carcinoma: Diagnostic imaging Techniques; Biopsy Procedures; Molecular Diagnostic Tests
• 2) By Squamous Cell Carcinoma: Diagnostic imaging Techniques; Biopsy Procedures; Molecular Diagnostic Tests
• 3) By Malignant Melanoma: Diagnostic Imaging Techniques; Biopsy Procedures; Molecular Diagnostic Tests
• 4) By Other Cancer Types: Non-Melanoma Skin Cancers; Dermatofibrosarcoma Protuberans; Merkel Cell Carcinoma
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Limited; Merck & Co.; Bayer AG; Novartis AG; Bristol-Myers Squibb Company; Sanofi; Eli Lilly and Company; Canon Medical Systems Corporation; Amgen Inc.; GE Healthcare; Daiichi Sankyo Company Limited.; National Cancer Institute; Agilent Technologies Inc.; bioMerieux SA; Teva Pharmaceutical Industries; Bruker Corp; Almirall; Genentech; Castle Biosciences; Sun Pharmaceutical Industries Limited.; American Academy of Dermatology; Biolitec Ag; Alma Lasers; DermTech Inc.; SkylineDx BV; DermLite LLC; AMLo Biosciences Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Skin Cancer Diagnostics Market Characteristics

3. Skin Cancer Diagnostics Market Trends And Strategies

4. Skin Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Skin Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Skin Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Skin Cancer Diagnostics Market Growth Rate Analysis
• 5.4. Global Skin Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Skin Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Skin Cancer Diagnostics Total Addressable Market (TAM)

6. Skin Cancer Diagnostics Market Segmentation

• 6.1. Global Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Basal Cell Carcinoma
• Squamous Cell Carcinoma
• Malignant Melanoma
• Other Cancer Types
• 6.2. Global Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnosis
• Therapeutics
• 6.3. Global Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinic
• Laboratory
• Other Applications
• 6.4. Global Skin Cancer Diagnostics Market, Sub-Segmentation Of Basal Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Imaging Techniques
• Biopsy Procedures
• Molecular Diagnostic Tests
• 6.5. Global Skin Cancer Diagnostics Market, Sub-Segmentation Of Squamous Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Imaging Techniques
• Biopsy Procedures
• Molecular Diagnostic Tests
• 6.6. Global Skin Cancer Diagnostics Market, Sub-Segmentation Of Malignant Melanoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Imaging Techniques
• Biopsy Procedures
• Molecular Diagnostic Tests
• 6.7. Global Skin Cancer Diagnostics Market, Sub-Segmentation Of Other Cancer Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Melanoma Skin Cancers
• Dermatofibrosarcoma Protuberans
• Merkel Cell Carcinoma

7. Skin Cancer Diagnostics Market Regional And Country Analysis

• 7.1. Global Skin Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Skin Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Skin Cancer Diagnostics Market

• 8.1. Asia-Pacific Skin Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Skin Cancer Diagnostics Market

• 9.1. China Skin Cancer Diagnostics Market Overview
• 9.2. China Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Skin Cancer Diagnostics Market

• 10.1. India Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Skin Cancer Diagnostics Market

• 11.1. Japan Skin Cancer Diagnostics Market Overview
• 11.2. Japan Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Skin Cancer Diagnostics Market

• 12.1. Australia Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Skin Cancer Diagnostics Market

• 13.1. Indonesia Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Skin Cancer Diagnostics Market

• 14.1. South Korea Skin Cancer Diagnostics Market Overview
• 14.2. South Korea Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Skin Cancer Diagnostics Market

• 15.1. Western Europe Skin Cancer Diagnostics Market Overview
• 15.2. Western Europe Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Skin Cancer Diagnostics Market

• 16.1. UK Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Skin Cancer Diagnostics Market

• 17.1. Germany Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Skin Cancer Diagnostics Market

• 18.1. France Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Skin Cancer Diagnostics Market

• 19.1. Italy Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Skin Cancer Diagnostics Market

• 20.1. Spain Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Skin Cancer Diagnostics Market

• 21.1. Eastern Europe Skin Cancer Diagnostics Market Overview
• 21.2. Eastern Europe Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Skin Cancer Diagnostics Market

• 22.1. Russia Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Skin Cancer Diagnostics Market

• 23.1. North America Skin Cancer Diagnostics Market Overview
• 23.2. North America Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Skin Cancer Diagnostics Market

• 24.1. USA Skin Cancer Diagnostics Market Overview
• 24.2. USA Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Skin Cancer Diagnostics Market

• 25.1. Canada Skin Cancer Diagnostics Market Overview
• 25.2. Canada Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Skin Cancer Diagnostics Market

• 26.1. South America Skin Cancer Diagnostics Market Overview
• 26.2. South America Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Skin Cancer Diagnostics Market

• 27.1. Brazil Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Skin Cancer Diagnostics Market

• 28.1. Middle East Skin Cancer Diagnostics Market Overview
• 28.2. Middle East Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Skin Cancer Diagnostics Market

• 29.1. Africa Skin Cancer Diagnostics Market Overview
• 29.2. Africa Skin Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Skin Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Skin Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Skin Cancer Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Skin Cancer Diagnostics Market Competitive Landscape
• 30.2. Skin Cancer Diagnostics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Skin Cancer Diagnostics Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. Sanofi
• 31.3. Eli Lilly and Company
• 31.4. Canon Medical Systems Corporation
• 31.5. Amgen Inc.
• 31.6. GE Healthcare
• 31.7. Daiichi Sankyo Company Limited.
• 31.8. National Cancer Institute
• 31.9. Agilent Technologies Inc.
• 31.10. bioMerieux SA
• 31.11. Teva Pharmaceutical Industries
• 31.12. Bruker Corp
• 31.13. Almirall
• 31.14. Genentech
• 31.15. Castle Biosciences

32. Global Skin Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Skin Cancer Diagnostics Market

34. Recent Developments In The Skin Cancer Diagnostics Market

35. Skin Cancer Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Skin Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Skin Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Skin Cancer Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer